CN104208250B - 一种治疗艾滋病的药物组合物 - Google Patents
一种治疗艾滋病的药物组合物 Download PDFInfo
- Publication number
- CN104208250B CN104208250B CN201410489481.7A CN201410489481A CN104208250B CN 104208250 B CN104208250 B CN 104208250B CN 201410489481 A CN201410489481 A CN 201410489481A CN 104208250 B CN104208250 B CN 104208250B
- Authority
- CN
- China
- Prior art keywords
- radix
- aids
- pharmaceutical composition
- treatment
- acquired immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000030507 AIDS Diseases 0.000 title claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 25
- 241000238659 Blatta Species 0.000 abstract description 2
- 230000007812 deficiency Effects 0.000 abstract description 2
- 241000271039 Agkistrodon Species 0.000 abstract 1
- 241000208340 Araliaceae Species 0.000 abstract 1
- 241001161070 Calomela Species 0.000 abstract 1
- 244000153234 Hibiscus abelmoschus Species 0.000 abstract 1
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 abstract 1
- 241001646826 Isodon rubescens Species 0.000 abstract 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract 1
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 1
- 241000238661 Periplaneta Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 235000008434 ginseng Nutrition 0.000 abstract 1
- 229910052957 realgar Inorganic materials 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010024604 Lipoatrophy Diseases 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 229940124321 AIDS medicine Drugs 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 241001183967 Isodon Species 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010053961 Mitochondrial toxicity Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 201000001322 T cell deficiency Diseases 0.000 description 1
- 208000027912 T-cell immunodeficiency Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- BPYKTIZUTYGOLE-UHFFFAOYSA-N billirubin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(C=C3C(=C(C=C)C(=O)N3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 231100000296 mitochondrial toxicity Toxicity 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种治疗艾滋病的药物组合物。所述的药物组合物以下述重量份的原料制成：人参12-24份、柴胡12-24份、苦参12-24份、蒲公英12-24份、大青叶12-24份、洗手果12-24份、青黛12-24份、轻粉12-24份、麝香12-24份、雄黄9-21份、狼毒9-21份、蕲蛇9-21份、喜树9-21份、雷公藤9-21份、徐长卿9-21份、蟑螂9-21份、冬凌草9-21份为活性成分，克服现有治疗艾滋病药物的不足，提供一种治疗艾滋病效果较好的药物组合物。
Description
技术领域
本发明涉及中药技术领域，具体涉及一种治疗艾滋病的药物组合物。
背景技术
艾滋病，即获得性免疫缺陷综合征(AcquiredImmunodeficiencySyndrome,AIDS)，是由人类免疫缺陷病毒(HumanImmundeficiencyVirus,HIV)感染引起的慢性传染病。在人类免疫缺陷病毒直接或间接作用下，T细胞免疫缺陷，同时其他免疫细胞均不同程度受损，促使各种严重的机会性感染和肿瘤发生，导致死亡。具体的，HIV通过攻击人体免疫系统，破坏免疫平衡，从而使人体感染其它疾病，导致各种复合感染而死亡。HIV病毒感染宿主细胞后，大量繁殖、破坏CD4+T淋巴细胞，使机体抵抗力下降，导致各种复合感染发生而死亡。常见的感染如：丙肝、肺结核、真菌感染、带状疱疹、卡氏肺孢子虫肺炎、脑炎以及恶性肿瘤的发生等。
艾滋病不仅已成为严重威胁人民健康的公共卫生问题，且已影响到经济发展和社会稳定。在治疗艾滋病的药物的毒副作用方面，瑞士的一组HIV研究中显示，接受抗逆转录病毒治疗((ART)的病人中，有45％的病人出现临床不良事件，27％的病人出现实验室不良事件。药物相关的事件可能出现在早期(治疗的前几周或几个月)，出现在早期的主要副作用包括消化道症状，难以忍受的恶心、呕吐、腹泻、腹痛以及特定药物如AZT的骨髓抑制，EFV的头痛、头晕、恶梦，甚至精神障碍；非核苷类药物引起的皮疹以及肝功能异常；ABC引起的发热、全身不适以及呼吸困难；IDV引起的肾结石；ATV引起的间接胆红素升高等。药物相关的事件也可能出现在晚期(6个月之后或者更长)。晚期的副作用主要包括代谢的并发症和形态的改变，长期服用核苷类药物所引起的线粒体毒性，如严重的乳酸酸中毒、肌病、心肌病、胰腺炎、末梢神经炎；蛋白酶抑制剂所引起的代谢异常，脂肪代谢障碍，出现四肢、臀部以及面部等周围皮下脂肪萎缩而中央躯干脂肪堆积，与脂肪萎缩相关的代谢特性包括：高甘油三酯血症、高胆固醇血症、胰岛素抵抗、乳酸血症，骨密度减低以及由于高脂血症和胰岛素抵抗而增加心血管疾病的危险。
现代医学防治艾滋病采用的是抗病毒、提高机体免疫、控制和治疗各种机会性感染症，但药物作用单一，往往需要多药并用，药价昂贵，毒副作用大。中国艾滋病治疗用药主要依靠进口，年人均药品费用至少需人民币3万-5万元。同时，国家在艾滋病控制方面的投入也急剧增加。
发明内容
本发明要解决的技术问题是克服现有治疗艾滋病药物的不足，提供一种治疗艾滋病效果较好的药物组合物。
本发明药物组合物中各组分的用量是发明人经过大量实践总结得出的，由下述重量份的原料制成：
优选地，它是由下列原料按重量份计制成：
更优选地，它是由下列原料按重量份计制成：
本发明所述药物组合物的剂型可以是胶囊、丸剂、片剂、汤剂等医学上可接受的剂型，它们的制备方法、辅料用量按现有常规工艺进行。
本发明还包括上述药物组合物在制备治疗艾滋病的药物中的应用。
本发明所述药物组合物组方中：
雄黄--具有散和排肿解毒、抗癌肿作用；
人参--具有大补元气、利水固脱作用；
柴胡--具有疏肝清热、升阳作用；
苦参--具有凉血化湿、消肿解毒作用；
蒲公英--具有清热解毒、利湿通淋作用；
大青叶--具有凉血、清热解毒作用；
洗手查--具有凉血、清血化毒作用；
青黛--具有凉血、祛血毒作用；
轻粉--具有去腐生肌、抗癌作用；
麝香--具有开窍、排脓、抗癌作用；
狼毒--具有活血止痛、排脓抗癌作用；
蕲蛇--具有散结排脓、去疮、抗癌作用；
喜树--具有凉血行气、破积、抗癌作用；
徐长卿--具有凉血止痛、抗癌作用；
雷公藤--具有强体、免疫功能提高、解毒作用；
冬凌草--具有清热解毒、止血止痛、抗癌肿作用；
蟑螂--具有破瘀定惊、泻火攻毒、抗癌肿、蛋白质对淋巴细胞白血病有边缘活性作用。
本发明药物组合物纯中药组合，具有良好的治疗艾滋病毒作用，抗艾滋病毒功能十分明显，固体清毒、抗癌作用，快速阻断艾滋病毒破坏各器官，保护造血功能系统。以清解血毒、扶正养血清毒之效。
具体实施方式
下面以具体实施例对本发明作进一步说明，但本发明并不局限于这些实施例。
实施例1
称取以上各原料，洗净烘干，混合粉碎过80目筛，加炼蜜为丸，得丸剂。
实施例2
按配比量称取以上各原料，加水煎煮两次，第一次加7倍量水，煎煮1.5小时，第二次加8倍量水，煎煮1.5小时，合并煎液，过滤，滤液浓缩至相对密度为1.30(70℃时测)的浸膏，加入适量的蔗糖粉，按常规工艺制成颗粒剂。
实施例3
称取以上各原料，加水煎煮两次，第一次加8倍量水，煎煮2小时，第二次加6倍量水，煎煮1.5小时，合并煎液，过滤，得汤剂。
实施例4
按配比量称取以上各原料，加水煎煮两次，第一次加7倍量水，煎煮1.5小时，第二次加8倍量水，煎煮1.5小时，合并煎液，过滤，滤液浓缩至相对密度为1.30(70℃时测)的浸膏，加入常规用量的硬脂酸镁辅料，按常规工艺制成片剂，规格0.5g/片。
实施例5
按配比量称取以上各原料，加水煎煮两次，第一次加7倍量水，煎煮1.5小时，第二次加8倍量水，煎煮1.5小时，合并煎液，过滤，滤液浓缩至相对密度为1.30(70℃时测)的浸膏，加入常规用量的糊精辅料，按常规工艺，制成胶囊，0.5g/粒。
实验例：本发明实施例5治疗艾滋病临床疗效观察：
本发明所述的中药组合物临床试验统计如下:
1、病例及方法
2008-2014年，在广西某省级医院针对艾滋病患者及性能进行治疗，患者68例，男性36例，女性32例，平均年龄38岁。所有病例自愿接受临床研究，从未接受过抗病毒药物治疗。
诊断标准：所有病例均符合HIV/AIDS诊断标准。
治疗方法：本发明实施例5，胶囊，每日3次，每次2粒，口服；30d为1个疗程，停药1-3d后，可进行下一疗程，连用2个疗程。
2、疗效判定
临床疗效评定标准：根据国家中医药管理局制定的《中医药治疗艾滋病试点项目临床技术方案》，疗效评价标准如下:
有效：临床症状体征改善明显，总积分下降≥1/3；CD4升高≥30％或50ul；病毒载量降低＞0.51og/ml。
稳定：临床症状体征有所改善，总积分下降＜1/3；CD4升高＜30％或50ul；病毒载量上升或下降＜0.51og/ml。
无效：临床症状体征无改善或加重，总积分不下降或增加；CD4下降≥30％或50u1；病毒载量水平持续上升，拷贝数上升＞0.51og/ml。
3、疗效总结
| 例数 | 有效 | 稳定 | 无效 | 有效率 |
| 治疗前后体征变化 | 51 | 14 | 3 | 95.6％ |
| 治疗前后CD4变化 | 50 | 16 | 2 | 97.0％ |
| 治疗前后病毒载量变化 | 44 | 13 | 11 | 83.8％ |
临床观察结果表明：服用本发明实施例5胶囊治疗的68例艾滋病患者，明显改善症状、提高CD4、抑制病毒复制等有明显的疗效。
Claims (4)
1.一种治疗艾滋病的药物组合物，其特征在于：该药物组合物是由下述重量份的原料制成：
2.根据权利要求1所述的治疗艾滋病的药物组合物，其特征在于：该药物组合物是由下述重量份的原料制成：
3.根据权利要求1所述的治疗艾滋病的药物组合物，其特征在于：该药物组合物是由下述重量份的原料制成：
4.权利要求1-3中任一项所述的药物组合物在制备治疗艾滋病的药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410489481.7A CN104208250B (zh) | 2014-09-23 | 2014-09-23 | 一种治疗艾滋病的药物组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410489481.7A CN104208250B (zh) | 2014-09-23 | 2014-09-23 | 一种治疗艾滋病的药物组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104208250A CN104208250A (zh) | 2014-12-17 |
| CN104208250B true CN104208250B (zh) | 2016-04-27 |
Family
ID=52090423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410489481.7A Active CN104208250B (zh) | 2014-09-23 | 2014-09-23 | 一种治疗艾滋病的药物组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104208250B (zh) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1245707A (zh) * | 1999-08-12 | 2000-03-01 | 黄英秀 | 一种治疗艾滋病及癌症的药物 |
| CN101444596A (zh) * | 2008-06-05 | 2009-06-03 | 魏建华 | 一种治疗艾滋病的中药 |
| CN101524468A (zh) * | 2009-03-23 | 2009-09-09 | 李卓伦 | 治疗艾滋病的药物 |
-
2014
- 2014-09-23 CN CN201410489481.7A patent/CN104208250B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104208250A (zh) | 2014-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101703708B (zh) | 一种治疗类风湿关节炎、痛风的中药制剂及其制备方法 | |
| CN101357219B (zh) | 一种用于治疗慢性乙型肝炎的药物 | |
| CN102178800B (zh) | 一种治疗类风湿性关节炎的中药组合物及其制备方法 | |
| CN103830632A (zh) | 一种根治银屑病等多种皮肤病的中药制剂及其制备方法与应用 | |
| CN102357155B (zh) | 一种治疗带状疱疹的中药组合物 | |
| CN103223069A (zh) | 一种治疗肝炎的中药组合物 | |
| CN102552512B (zh) | 一种治疗乙肝的中药组合物 | |
| CN1330359C (zh) | 一种治疗艾滋病的中药制剂及其加工方法 | |
| CN104587398A (zh) | 一种中药微生物发酵制剂及其制备方法与应用 | |
| CN104208250B (zh) | 一种治疗艾滋病的药物组合物 | |
| CN104189861A (zh) | 一种治疗面瘫的中药 | |
| CN102908443A (zh) | 一种治疗或辅助治疗艾滋病的药物组合物及其制备方法和用途 | |
| CN102805810B (zh) | 一种治疗艾滋病的中药制剂及相应的制备方法 | |
| CN105456924A (zh) | 含有艾叶的具有活血化瘀功能的中药制剂及其制备方法 | |
| CN110478416A (zh) | 治疗风湿性类风湿性关节炎的组合物及其制备方法和应用 | |
| CN103041260B (zh) | 一种治疗艾滋病的中药组合物及制备工艺 | |
| CN103585291B (zh) | 一种展毛翠雀提取物在制备治疗艾滋病药物中的应用 | |
| CN103768454A (zh) | 一种具有预防和治疗hiv/aids的组合物及其制备方法 | |
| CN102764325B (zh) | 祛湿除痛中药组合物 | |
| CN101721652A (zh) | 一种治疗肝病的药物及其制作方法 | |
| CN101732469A (zh) | 一种中药组合物在制备治疗失音症药物中的应用 | |
| CN101062340A (zh) | 养肝复原中药组合物 | |
| CN103585259B (zh) | 一种白花油麻藤提取物在制备治疗艾滋病药物中的应用 | |
| CN103585222B (zh) | 一种褐毛橐吾提取物在制备治疗艾滋病药物中的应用 | |
| CN1229133C (zh) | 一种治疗病毒性肝炎的药物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181128 Address after: 233010 Pioneering Building 316, Huineng Small and Micro Enterprises Pioneering Center, 1750 Shengli West Road, Yuhui District, Bengbu City, Anhui Province Patentee after: Bengbu Dingrong Science and Technology Information Consulting Co., Ltd. Address before: 535008 Legou Village, Yalujiang Village Committee, Qinzhou Port District, Qinzhou City, Guangxi Zhuang Autonomous Region Patentee before: Li Shaohua |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190412 Address after: Room 107, Building No. 28, Hexili, Xiba, Chaoyang District, Beijing Patentee after: Li Qiannan Address before: 233010 Pioneering Building 316, Huineng Small and Micro Enterprises Pioneering Center, 1750 Shengli West Road, Yuhui District, Bengbu City, Anhui Province Patentee before: Bengbu Dingrong Science and Technology Information Consulting Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191107 Address after: Ganquan road Shushan District of Hefei City, Anhui Province, 230000 West hillock road to the South Wild Garden commercial office building room B-1512 Patentee after: Anhui Eagle Dragon Industrial Design Co., Ltd. Address before: Room 107, Building No. 28, Hexili, Xiba, Chaoyang District, Beijing Patentee before: Li Qiannan |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211203 Address after: 276000 No. 30, Xiangyu Road, economic and Technological Development Zone, Linyi City, Shandong Province Patentee after: XIANGYU PHARMACEUTICAL Co.,Ltd. Address before: 230000 B-1512, west of Ganquan Road, Shushan District, Hefei, Anhui. Patentee before: ANHUI YINGLONG INDUSTRIAL DESIGN Co.,Ltd. |